[{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"APN01","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"APN01","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"APN401","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ APEIRON","highestDevelopmentStatusID":"6","companyTruncated":"Apeiron Biologics \/ APEIRON"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Alunacedase alfa","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Domainex","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"APN431","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ APEIRON Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Apeiron Biologics \/ APEIRON Biologics"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Sensei Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Series B Financing","leadProduct":"Pembrolizumab","moa":"Aspartyl beta hydroxylase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Apeiron Biologics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"injection","sponsorNew":"Apeiron Biologics \/ Apeiron","highestDevelopmentStatusID":"7","companyTruncated":"Apeiron Biologics \/ Apeiron"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Bionomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"nAChR Alpha7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral suspension","sponsorNew":"Apeiron Biologics \/ Apeiron","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Apeiron"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Alunacedase Alfa","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalational","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Alunacedase Alfa","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Apeiron Biologics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Apeiron Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Apeiron Biologics","amount2":0.13,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Apeiron Biologics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

                          Brand Name : Qarziba

                          Molecule Type : Large molecule

                          Upfront Cash : $100.0 million

                          July 08, 2024

                          Lead Product(s) : Dinutuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $128.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The study met all primary and secondary endpoints, with all results indicating that the inhalation of APN01 (alunacedase alfa) at all dosage levels used in the trial is safe and well tolerated.

                          Brand Name : APN01

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 02, 2022

                          Lead Product(s) : Alunacedase Alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Primary study objective is the evaluation of safety and tolerability of single ascending doses (SADs) and multiple ascending doses (MADs) of inhaled APN01 when administered via a jet nebulizer in healthy subjects.

                          Brand Name : APN01

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 12, 2021

                          Lead Product(s) : Alunacedase Alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the Subscription Agreement dated 2 June 2020 with Apeiron, Apeiron agreed to recapitalise the Company and assist in securing further equity capital to fund the Company's BNC210 Phase 2b Clinical trial for the treatment of post-traumatic stress diso...

                          Brand Name : BNC210

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          February 10, 2021

                          Lead Product(s) : BNC210

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Recipient : Bionomics

                          Deal Size : Undisclosed

                          Deal Type : Financing

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Sensei’s lead ImmunoPhage product candidate, SNS301, is being evaluated in a Phase 1/2 trial for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab.

                          Brand Name : SNS-301

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          January 11, 2021

                          Lead Product(s) : SNS-301,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Sensei Biotherapeutics

                          Deal Size : $30.0 million

                          Deal Type : Series B Financing

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Domainex will provide its expertise in medicinal and computational chemistry, screening, structural biology and ADME/PK to advance APEIRON’s promising Cbl-b targeting compound series APN431 towards pre-clinical development.

                          Brand Name : APN431

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 09, 2020

                          Lead Product(s) : APN431

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Domainex

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Case study from promising first COVID-19 patient treatment with APN01 supports APEIRON’s ongoing pivotal Phase II clinical trial.

                          Brand Name : APN01

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 25, 2020

                          Lead Product(s) : Alunacedase alfa

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Under the terms of this licensing agreement, APEIRON to utilize MaxCyte's ExPERT® platform for siRNA-based cell therapy APN401 targeting solid tumors and secures manufacturing for upcoming clinical trials.

                          Brand Name : APN401

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          July 07, 2020

                          Lead Product(s) : APN401

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : MaxCyte

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Regulatory approvals obtained for the treatment of 200 COVID-19 patients in Austria, Germany and Denmark; Austrian government to provide significant financial support.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 02, 2020

                          Lead Product(s) : APN01

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The randomized, unblinded trial will treat 24 patients for seven days to obtain preliminary data on the impact of rhACE2 on biological, physiologic, and clinical outcomes and safety in patients.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          February 26, 2020

                          Lead Product(s) : APN01

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank